We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Verici Dx Plc | VRCI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.25 | 07:36:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.25 | 7.25 | 7.25 | 7.25 | 7.25 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 21/2/2024 19:58 by bmcollins Two very well regarded VCT/small co's managers as well, seems like raising cash was no problem for VRCI with backers like these. |
Posted at 21/2/2024 11:06 by toffeeman Unicorn paid 6.3p per share.They are uninterested in the share price over the next 5 years. If the company is still independent then they may be paying dividend by then and the VCT pays them to their shareholders tax free. If the company is acquired then Unicorn can pay out a special divi to their shareholders which again is tax free. Treat Unicorn as a passive investor with no impact on the share price. |
Posted at 21/2/2024 09:59 by bmcollins Excuse me if I appear rather thick but after a vct greatly increasing their stake in VRCI that not only does the price not go up it actually falls back to its levels pre announcement of the size of the purchase.What am I missing (please nobody say profit) ? |
Posted at 13/12/2023 08:44 by wan I have said this before, and even though Verici has conmpleted a deal with Thermo, I am still of the opinion that Verici must surely still be in the sights of potential partners given the changing backdrop to transplant testing in the US, and indeed the patent situation -Court Denies CareDx Motion for Summary Judgement on Two Natera Patents Dec 12, 2023 NEW YORK – Natera said on Monday that the US District Court for the District of Delaware denied CareDx's motion for summary judgement on two patents held by Natera that form part of a lawsuit that Natera filed against CareDx. Full story - Cue the recent strengthening of Verici's intellectual property portfolio - |
Posted at 11/12/2023 08:43 by brummy_git Continued positive news & strong execution at expert immunodiagnostics firm, Verici DxAll the details here. |
Posted at 24/11/2023 16:35 by toffeeman I think that VRCI and GENI are suffering from RENX disease |
Posted at 15/11/2023 08:19 by brummy_git Blockbuster licensing deal announced today by expert immunodiagnostics firm Verici DxMrkcap £10m) with Thermo Fisher All the details here. |
Posted at 15/11/2023 07:19 by cliveas Nice Jv bringing in $5m with further benefits.For me this only has to be the start of the money rollercoaster that VRCI are going to create. Literally they are taking the urine! 'In addition, Verici Dx has granted Thermo Fisher a non-exclusive license for access to a portion of the Company's urine samples, demonstrating the additional value in the Company's data and sample assets for research.' They were already fully funded until mid 2024 so no placings ahoy! GL. |
Posted at 29/9/2023 08:47 by brummy_git Terrific progress being made on the R&D front from Verici Dx.Albeit initial adoption of its state-of-the-art kidney transplant test (Tutivia) appears to be taking longer than originally anticipated. All the details here. |
Posted at 20/7/2023 07:24 by oapknob1 Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that further to the RNS dated 2 March 2023 , the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional four US states, including the important addition of California , with the Company laboratory now fully accredited in a total of 49 states. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
